Skip to content

OS Therapies OSTX Income Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$22.4M+492%$16.36M+476%$8.43M+182%$5.89M+164%$3.79M+33.9%
$11.47M+55.1%$12.34M+211%$11.25M+458%$9.35M+877%$7.4M+574%
-$33.87M-203%-$28.71M-321%-$19.68M-293%-$15.24M-378%-$11.18M-185%
-$1.4M-1,089%-$48.14K+97.7%$1.4M+160%$962.08K+129%-$117.7K+96.6%
-$35.27M-212%-$28.75M-224%-$18.28M-149%-$14.28M-121%-$11.3M-52.6%
-$1.08+14.3%-$0.99+25.6%-$1.22+20.8%-$1.19+31.6%-$1.26+35.4%
-$33.39M-199%-$28.34M-316%-$19.44M-289%-$15.13M-375%-$11.18M-185%
-$33.87M-203%-$28.71M-321%-$19.68M-293%-$15.24M-378%-$11.18M-185%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is OS Therapies profitable?
OS Therapies is not currently profitable: it reported a net loss of $35.3M over the trailing twelve months.
What is OS Therapies's earnings per share?
OS Therapies's diluted EPS over the trailing twelve months is $-1.08.
Where does OS Therapies's income statement data come from?
Every line is extracted from OS Therapies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.